Compare CAG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAG | BLCO |
|---|---|---|
| Founded | 1919 | 1853 |
| Country | United States | Canada |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Ophthalmic Goods |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 5.9B |
| IPO Year | 1994 | 2022 |
| Metric | CAG | BLCO |
|---|---|---|
| Price | $14.09 | $16.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $16.88 | ★ $18.45 |
| AVG Volume (30 Days) | ★ 12.9M | 358.5K |
| Earning Date | 04-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 9.84% | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,500,000,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $13.86 | $10.83 |
| 52 Week High | $23.79 | $18.92 |
| Indicator | CAG | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 51.18 |
| Support Level | $14.04 | $16.26 |
| Resistance Level | $19.48 | $17.11 |
| Average True Range (ATR) | 0.37 | 0.47 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 21.36 | 56.18 |
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.